Covid Positive | Covid negative | Percent with feature | Percent COVID positive | Hazards ratio | 95% CI | P | Comments | ||
ALL PATIENTS | |||||||||
Sarcoidosis | 5 | 100 | 105 | 4.76% | |||||
Sarc patients | |||||||||
Male | 1 | 27 | 28 | 26.67% | 3.57% | 0.6875 | 0.08022-5.8917 | >0.05 | |
Female | 4 | 73 | 77 | 73.33% | 5.19% | ||||
Other | 0 | 2 | 2 | 1.90% | 0.00% | DNC | |||
White | 5 | 97 | 02 | 97.14% | 4.90% | 1 No Answer | |||
Current meds | |||||||||
Prednisone | 2 | 40 | 42 | 40.00% | 4.76% | 1 | 0.1745-5.7322 | >0.05 | |
No prednisone | 3 | 60 | 63 | 60.00% | 4.76% | ||||
Prednisone ≥ 10 mg | 0 | 19 | 19 | 18.10% | 0.00% | 0.24 | 0.01222-4.715 | >0.05 | |
Prednisone < 10mg | 2 | 21 | 23 | 21.90% | 8.70% | ||||
Plaquenil | 0 | 6 | 6 | 5.71% | 0.00% | 1.2987 | 0.07692-21.834 | >0.05 | |
No plaquenil | 5 | 94 | 99 | 94.29% | 5.05% | ||||
anti-TNF | 1 | 6 | 7 | 6.67% | 14.29% | 3.5 | 0.4493-27.264 | >0.05 | |
no anti-TNF | 4 | 94 | 98 | 93.33% | 4.08% | ||||
Cytotoxic | 0 | 19 | 19 | 18.10% | 0.00% | 0.3955 | 0.02278-6.8641 | >0.05 | |
No cytotoxic | 5 | 81 | 86 | 81.90% | 5.81% | ||||
Rituximab | 0 | 0 | 0 | 0.00% | 0.00% | DNC | |||
No rituximab | 5 | 100 | 105 | 100.00% | 4.76% | ||||
Underlying | |||||||||
COPD | 0 | 12 | 12 | 11.43% | 0.00% | 0.6573 | 0.03854-11.2108 | >0.05 | |
5 | 88 | 93 | 88.57% | 5.38% | |||||
Diabetes | 1 | 19 | 20 | 19.05% | 5.00% | 1.0625 | 0.1254-8.9993 | >0.05 | |
4 | 81 | 85 | 80.95% | 4.71% | |||||
105 | |||||||||
Heart disease | 0 | 5 | 5 | 4.76% | 0.00% | 1.5303 | 0.09537-24.5561 | >0.05 | |
5 | 95 | 100 | 95.24% | 5.00% | |||||
105 | |||||||||
Hypertension | 0 | 15 | 15 | 14.29% | 0.00% | 0.517 | 0.3003-8.9023 | >0.05 | |
5 | 85 | 90 | 85.71% | 5.56% | |||||
105 | |||||||||
Organ involved | 2 no answer | ||||||||
Lung | 4 | 93 | 97 | 92.38% | 4.12% | 0.2474 | 0.3249-1.8845 | >0.05 | |
1 | 5 | 6 | 5.71% | 16.67% | |||||
103 | |||||||||
Cardiac sarc | 0 | 4 | 4 | 3.81% | 0.00% | 1.8182 | 0.116-28.5055 | >0.05 | |
5 | 94 | 99 | 94.29% | 5.05% | |||||
103 | |||||||||
Neuro sarc | 2 | 6 | 8 | 7.62% | 25.00% | 7.9167 | 1.5399-40.701 | 0.0133 | |
3 | 92 | 95 | 90.48% | 3.16% | |||||
103 | |||||||||
Origin | |||||||||
SPAIN | 4 | 100 | 04 | 5.30% | 3.85% | ||||
NOT SPANISH | 1 | 0 | 1 | 0.05% | 100.00% | ||||
105 | |||||||||
Sarcoid age | |||||||||
Covid Positive | 49.80 ± 9.20years | 0.3 | |||||||
Covid negative | 44.88 ± 8.82 years | ||||||||
COVID outcome | Home | Hospital | ICU | Vent | |||||
Sarc | 4 | 1 | 0 | 0 | |||||
Sarc ≥ 5 yr | 4 | 63 | 67 | 3.51% | 5.97% | 5.0294 | 0.27827-90.9223 | >0.05 | 1 no answer |
Sarc < 5 yr | 0 | 37 | 37 | 1.94% | 0.00% | ||||
04 | |||||||||
COVID positive | Home | Hospital | Percen t on drug | Percent treated in hospital | If in hospital, considered | ||||
Prednisone | bad outcome | ||||||||
Yes | 2 | 0 | 2 | 3.03% | 0.00% | Hazard ration for | |||
No | 2 | 1 | 3 | 4.55% | 33.33% | Hospitalization | |||
Prednisone ≥ 10 mg | 0 | 0 | 0 | 0.00% | #DIV/0! | ||||
Prednisone < 10mg | 2 | 0 | 2 | 3.03% | 0.00% | ||||
Infliximab | |||||||||
Yes | 1 | 0 | 1 | 1.52% | 0.00% | ||||
No | 3 | 1 | 4 | 6.06% | 25.00% | ||||
Plaquenil | |||||||||
Yes | 0 | 0 | 0 | 0.00% | #DIV/0! | ||||
No | 4 | 1 | 5 | 7.58% | 20.00% | ||||
Cytotoxic | |||||||||
Yes | 0 | 0 | 0 | 0.00% | #DIV/0! | ||||
No | 4 | 1 | 5 | 7.58% | 20.00% | ||||
Rituximab | |||||||||
Yes | 0 | 0 | 0 | 0.00% | #DIV/0! | ||||
No | 4 | 1 | 5 | 7.58% | 20.00% | ||||
Covid Positive | Covid negative | ||||||||
Roommate | 0 | 2 | 2 | 1.90% | 0.00% | 3.0909 | 0.2167-44.087 | >0.05 | 2 no answer |
No roommate | 5 | 96 | 101 | 96.19% | 4.95% | ||||
Health provider | 3 | 13 | 16 | 15.24% | 18.75% | 8.0625 | 1.4614-44.4791 | 0.0166 | 3 no answer |
No healtg provider | 2 | 84 | 86 | 81.90% | 2.33% |